TGFB1 and neoplasm: Anti-TGFβ antibodies can break this cycle to reduce TGFβ signaling, reverse abnormal Treg/Th1 cell ratios, and promote tumor rejection and long-term antitumor immunity (Dodagatta-Marri et al. 2019).